Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01390714 · ClinicalTrials.gov registry record · Phase 1
Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects
A Phase 1 study of Gastroesophageal Reflux Disease, sponsored by Eisai Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01390714 is a Phase 1 study of Gastroesophageal Reflux Disease that has completed, run by Eisai Co.. The registered enrollment target is 30 participants, below the 346-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01390714, a Phase 1 study of Gastroesophageal Reflux Disease, has completed, sponsored by Eisai Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the pharmacodynamics (PD) and pharmacokinetics of E3710 following oral administration to Healthy Male Japanese Subjects
Conditions Studied
Interventions
- DRUG E3710
Study Locations (1)
California
- - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01390714
The ClinicalTrials.gov registry entry for NCT01390714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 346-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (91% lower). The listed sponsor is Eisai Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastroesophageal Reflux Disease appearing as the primary indexed condition, and to 1 intervention - of which E3710 is the first listed.
NCT01390714 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01390714 about?
NCT01390714 is a clinical study titled "Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects". The purpose of this study is to investigate the pharmacodynamics (PD) and pharmacokinetics of E3710 following oral administration to Healthy Male Japanese Subjects
What is the current status of trial NCT01390714?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-07. Estimated completion is 2011-10.
What conditions does trial NCT01390714 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux Disease.
What interventions are being tested in trial NCT01390714?
The interventions under investigation include: E3710 (DRUG).
Who is sponsoring clinical trial NCT01390714?
This trial is sponsored by Eisai Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01390714 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GCC Agonist Signal in the Small Intestine
ACTIVE NOT RECRUITING · Phase 1
-
Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
COMPLETED · Phase 1
-
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
COMPLETED · Phase 1
-
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
RECRUITING · NA
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.